Product business ownership
Viridyne VDX™
In the face of rising antibiotic resistance, VIRIDYNE VDX is pursuing a targeted approach to Staph infections. This development-stage topical biophage program uses genetically modified bacteriophages designed to target harmful bacteria, with the goal of sparing healthy cells. Viridyne Genetics is developing VDX to address antibiotic-resistant infections. VDX is not an approved drug. Any potential access under Right to Try depends on eligibility and the developer’s agreement; immediate availability is not guaranteed.
Offered at: $195K 1 Year Consulting Included
Ownership opportunity.
The $195K offer concerns product business ownership, not an individual retail product purchase. One year of consulting is included.
Confirm ownership terms and availability, development stage, specifications, regulatory status, patent status, and final transaction terms directly with Atlantium AI. Performance claims require independent testing and validation. Viridyne VDX is development-stage and is not an approved drug.